Modernizing the Global Postal System: Zonos Selected by the Universal Postal Union (UPU) to Power Enhanced Compliance, Processing Speed, and Transparency for Posts Worldwide
4.9.2024 17:00:00 EEST | Business Wire | Press release
In a groundbreaking move to address the dual challenges of evolving compliance regulations and increasing consumer expectations for swift, efficient deliveries, Zonos, the leader in cross-border technology solutions, has been selected by the Universal Postal Union (UPU) for a strategic initiative. The UPU is a United Nations specialized agency that facilitates international postal cooperation through its universal network of modern postal services. By leveraging Zonos' cutting-edge API technology to enhance the accuracy and processing speed of data transmitted through the UPU's Customs Declaration System (CDS), this effort is poised to transform the global postal ecosystem. This initiative aims to empower postal operators with technology to mitigate delays caused by inadequate or incomplete data, thereby improving operational efficiency, ensuring compliance, and significantly enhancing the delivery experience for consumers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904490189/en/
The international DDP shipping model allows parcels to ship with duties, taxes, and fees prepaid, making it easy for packages to move through customs. (Graphic: Business Wire)
Bridging the Technological Divide for Postal Operators Worldwide
This partnership specifically targets the technological challenges faced by postal operators around the globe. Many of these entities struggle to compete in an increasingly digital and data-driven landscape due to their limited ability to accurately and rapidly transmit electronic advanced data (EAD). This deficiency places them at a competitive disadvantage and contributes to significant delays in the international customs clearance process.
Zonos' innovative API technology offers a scalable and adaptable technology solution to these challenges, facilitating real-time, accurate data collection that meets the rigorous requirements of modern customs and security regulations that require detailed shipment information including good descriptions, harmonized codes, and accurate values for general or regional (such as ICS2) EAD regulations. The improved data quality addresses regulatory and safety concerns about the contents of packages for global customs operations.
Transitioning to a Delivered Duty Paid (DDP) Model
A significant goal of this collaboration is to transition towards a DDP model in response to market demand for more transparent and efficient customs processes. This initiative supports the UPU's Article 18-004 (Items for delivery free of charges and fees) by developing a robust DDP solution, facilitating smoother and faster cross-border mail and parcel deliveries. By enabling posts to calculate and collect duties and taxes at the point of sale, this model eliminates surprise costs for consumers and enhances the overall international mailing and delivery experience.
Enhancing Consumer Experience through Efficiency and Reliability
The UPU-Zonos initiative emphasizes improving the delivery experience for consumers worldwide. By streamlining the data collection process, the partnership aims to expedite customs clearance and reduce the time packages spend in transit to meet the consumer demand for speed. It also aims to enhance the reliability and predictability of international deliveries, fostering greater trust in the global postal system.
A Unified Vision for the Future of International Postal Services
The shared commitment of the UPU and Zonos to leveraging technology for the betterment of the global postal ecosystem is at the heart of this initiative. Clint Reid, CEO of Zonos, echoed this sentiment, highlighting the transformative potential of the collaboration: "Together, we are not just addressing immediate challenges; we are paving the way for a future where international postal services are more secure, efficient, and transparent for all."
About Zonos
Zonos is a leader in technology innovation for international commerce, simplifying cross-border trade with its comprehensive suite of solutions. Focused on compliance, classification, and transparent cost calculation, Zonos empowers businesses and postal operators to expand their global reach effortlessly, making international trade more accessible and transparent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904490189/en/
Contacts
Jennifer Meads, Head of Marketing at Zonos
media@zonos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom